Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.

Palomo L, Garcia O, Arnan M, Xicoy B, Fuster F, Cabezón M, Coll R, Ademà V, Grau J, Jiménez MJ, Pomares H, Marcé S, Mallo M, Millá F, Alonso E, Sureda A, Gallardo D, Feliu E, Ribera JM, Solé F, Zamora L.

Oncotarget. 2016 Aug 30;7(35):57021-57035. doi: 10.18632/oncotarget.10937.

2.

Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.

Elena C, Gallì A, Such E, Meggendorfer M, Germing U, Rizzo E, Cervera J, Molteni E, Fasan A, Schuler E, Ambaglio I, Lopez-Pavia M, Zibellini S, Kuendgen A, Travaglino E, Sancho-Tello R, Catricalà S, Vicente AI, Haferlach T, Haferlach C, Sanz GF, Malcovati L, Cazzola M.

Blood. 2016 Sep 8;128(10):1408-17. doi: 10.1182/blood-2016-05-714030.

3.

Decitabine for the treatment of atypical chronic myeloid leukemia: A report of two cases.

Jiang H, Wu Z, Ren LI, Tao D, Tong H.

Oncol Lett. 2016 Jan;11(1):689-692.

4.

An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.

Mughal TI, Cross NC, Padron E, Tiu RV, Savona M, Malcovati L, Tibes R, Komrokji RS, Kiladjian JJ, Garcia-Manero G, Orazi A, Mesa R, Maciejewski JP, Fenaux P, Itzykson R, Mufti G, Solary E, List AF.

Haematologica. 2015 Sep;100(9):1117-30. doi: 10.3324/haematol.2014.114660.

5.

Chronic myelomonocytic leukemia: Forefront of the field in 2015.

Benton CB, Nazha A, Pemmaraju N, Garcia-Manero G.

Crit Rev Oncol Hematol. 2015 Aug;95(2):222-42. doi: 10.1016/j.critrevonc.2015.03.002. Review.

6.

Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia.

Niemeyer CM, Loh ML, Cseh A, Cooper T, Dvorak CC, Chan R, Xicoy B, Germing U, Kojima S, Manabe A, Dworzak M, De Moerloose B, Starý J, Smith OP, Masetti R, Catala A, Bergstraesser E, Ussowicz M, Fabri O, Baruchel A, Cavé H, Zwaan M, Locatelli F, Hasle H, van den Heuvel-Eibrink MM, Flotho C, Yoshimi A.

Haematologica. 2015 Jan;100(1):17-22. doi: 10.3324/haematol.2014.109892.

7.

Applicability of next-generation sequencing to decalcified formalin-fixed and paraffin-embedded chronic myelomonocytic leukaemia samples.

Bernard V, Gebauer N, Dinh T, Stegemann J, Feller AC, Merz H.

Int J Clin Exp Pathol. 2014 Mar 15;7(4):1667-76.

8.

Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.

Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, Stingo FC, Patel KP, Mehrotra M, Bueso-Ramos C, Young KH, Dinardo CD, Verstovsek S, Tiu RV, Bagg A, Hsi ED, Arber DA, Foucar K, Luthra R, Orazi A.

Blood. 2014 Apr 24;123(17):2645-51. doi: 10.1182/blood-2014-02-553800.

9.

Severe congenital neutropenia and chronic neutrophilic leukemia: an intriguing molecular connection unveiled by oncogenic mutations in CSF3R.

Touw IP, Beekman R.

Haematologica. 2013 Oct;98(10):1490-2. doi: 10.3324/haematol.2013.090571. No abstract available.

10.

Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups.

Onida F, Barosi G, Leone G, Malcovati L, Morra E, Santini V, Specchia G, Tura S.

Haematologica. 2013 Sep;98(9):1344-52. doi: 10.3324/haematol.2013.084020. Review.

11.

Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia.

Takahashi K, Pemmaraju N, Strati P, Nogueras-Gonzalez G, Ning J, Bueso-Ramos C, Luthra R, Pierce S, Cortes J, Kantarjian H, Garcia-Manero G.

Blood. 2013 Oct 17;122(16):2807-11; quiz 2920. doi: 10.1182/blood-2013-03-491399.

12.

Myelodysplastic syndromes: clinical practice guidelines in oncology.

Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM, Deeg HJ, Frankfurt O, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, O'Donnell MR, Shami PJ, Stein BL, Stone RM, Thompson JE, Westervelt P, Wheeler B, Shead DA, Naganuma M.

J Natl Compr Canc Netw. 2013 Jul;11(7):838-74.

13.
14.

Current concepts on the pathogenesis of the hypereosinophilic syndrome/chronic eosinophilic leukemia.

Yamada Y, Rothenberg ME, Cancelas JA.

Transl Oncogenomics. 2006 Dec 5;1:53-63.

15.

Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.

Gelsi-Boyer V, Cervera N, Bertucci F, Brecqueville M, Finetti P, Murati A, Arnoulet C, Mozziconacci MJ, Mills KI, Cross NC, Vey N, Birnbaum D.

Haematologica. 2013 Apr;98(4):576-83. doi: 10.3324/haematol.2012.071506.

16.

A Case of Atypical Delayed and Prolonged Hematologic Toxicity With Azacitidine in Chronic Myelomonocytic Leukemia (CMML) and Review of Literature.

Elli E, Cecchetti C, Belotti A, Borin L, Pogliani EM.

Mediterr J Hematol Infect Dis. 2012;4(1):e2012017. doi: 10.4084/MJHID.2012.017.

17.

Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions.

Muramatsu H, Makishima H, Maciejewski JP.

Semin Oncol. 2012 Feb;39(1):67-73. doi: 10.1053/j.seminoncol.2011.11.004. Review.

18.

Standards and impact of hematopathology in myelodysplastic syndromes (MDS).

Valent P, Orazi A, Büsche G, Schmitt-Gräff A, George TI, Sotlar K, Streubel B, Beham-Schmid C, Cerny-Reiterer S, Krieger O, van de Loosdrecht A, Kern W, Ogata K, Wimazal F, Várkonyi J, Sperr WR, Werner M, Kreipe H, Horny HP.

Oncotarget. 2010 Nov;1(7):483-96. Review.

19.

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P; National Comprehensive Cancer Network..

J Natl Compr Canc Netw. 2011 Jan;9(1):30-56.

20.

Cytogenetic risk stratification in chronic myelomonocytic leukemia.

Such E, Cervera J, Costa D, Solé F, Vallespí T, Luño E, Collado R, Calasanz MJ, Hernández-Rivas JM, Cigudosa JC, Nomdedeu B, Mallo M, Carbonell F, Bueno J, Ardanaz MT, Ramos F, Tormo M, Sancho-Tello R, del Cañizo C, Gómez V, Marco V, Xicoy B, Bonanad S, Pedro C, Bernal T, Sanz GF.

Haematologica. 2011 Mar;96(3):375-83. doi: 10.3324/haematol.2010.030957.

Items per page

Supplemental Content

Support Center